177 related articles for article (PubMed ID: 24327726)
1. Trends in clinical characteristics of HIV-infected patients initiating antiretroviral therapy in Shanghai from 2006 to 2011.
Shen Y; Wang J; Qi T; Wang Z; Lu H
Int J STD AIDS; 2014 Jun; 25(7):504-10. PubMed ID: 24327726
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial.
Laurent C; Kouanfack C; Koulla-Shiro S; Nkoué N; Bourgeois A; Calmy A; Lactuock B; Nzeusseu V; Mougnutou R; Peytavin G; Liégeois F; Nerrienet E; Tardy M; Peeters M; Andrieux-Meyer I; Zekeng L; Kazatchkine M; Mpoudi-Ngolé E; Delaporte E
Lancet; 2004 Jul 3-9; 364(9428):29-34. PubMed ID: 15234853
[TBL] [Abstract][Full Text] [Related]
3. Trends in the clinical characteristics of HIV-infected patients initiating antiretroviral therapy in Kenya, Uganda and Tanzania between 2002 and 2009.
Geng EH; Hunt PW; Diero LO; Kimaiyo S; Somi GR; Okong P; Bangsberg DR; Bwana MB; Cohen CR; Otieno JA; Wabwire D; Elul B; Nash D; Easterbrook PJ; Braitstein P; Musick BS; Martin JN; Yiannoutsos CT; Wools-Kaloustian K
J Int AIDS Soc; 2011 Sep; 14():46. PubMed ID: 21955541
[TBL] [Abstract][Full Text] [Related]
4. Baseline CD4 cell counts and outcomes among adult treatment naive HIV patients after taking fixed dose combination GPO-VIR-S and GPO-VIR-Z in Thailand.
Kyaw NL; Thanachartwet V; Kiertiburanakul S; Desakorn V; Chamnanchanunt S; Chierakul W; Manosuthi W; Pitisuttithum P; Sungkanuparph S
Southeast Asian J Trop Med Public Health; 2013 Mar; 44(2):232-43. PubMed ID: 23691633
[TBL] [Abstract][Full Text] [Related]
5. Superior Effectiveness of Zidovudine Compared With Tenofovir When Combined With Nevirapine-based Antiretroviral Therapy in a Large Nigerian Cohort.
Scarsi KK; Eisen G; Darin KM; Meloni ST; Rawizza HE; Tchetgen Tchetgen EJ; Agbaji OO; Onwujekwe DI; Gashau W; Nkado R; Okonkwo P; Murphy RL; Kanki PJ;
Clin Infect Dis; 2016 Feb; 62(4):512-8. PubMed ID: 26561532
[TBL] [Abstract][Full Text] [Related]
6. The effects of highly active antiretroviral therapy (HAART) of stavudine, lamivudine and nevirapine on the CD4 lymphocyte count of HIV-infected Africans: the Nigerian experience.
Erhabor O; Ejele OA; Nwauche CA
Niger J Clin Pract; 2006 Dec; 9(2):128-33. PubMed ID: 17319344
[TBL] [Abstract][Full Text] [Related]
7. Tolerability and effectiveness of first-line regimens combining nevirapine and lamivudine plus zidovudine or stavudine in Cameroon.
Laurent C; Bourgeois A; Mpoudi-Ngolé E; Ciaffi L; Kouanfack C; Mougnutou R; Nkoué N; Calmy A; Koulla-Shiro S; Delaporte E
AIDS Res Hum Retroviruses; 2008 Mar; 24(3):393-9. PubMed ID: 18327976
[TBL] [Abstract][Full Text] [Related]
8. Plasma nevirapine levels and 24-week efficacy of a fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) among Thai HIV-infected patients.
Manosuthi W; Kiertiburanakul S; Chaovavanich A; Sungkanuparph S
J Med Assoc Thai; 2007 Feb; 90(2):244-50. PubMed ID: 17375627
[TBL] [Abstract][Full Text] [Related]
9. A 72-week randomized study of the safety and efficacy of a stavudine to zidovudine switch at 24 weeks compared to zidovudine or tenofovir disoproxil fumarate when given with lamivudine and nevirapine.
Phanuphak N; Ananworanich J; Teeratakulpisarn N; Jadwattanakul T; Kerr SJ; Chomchey N; Hongchookiat P; Mathajittiphun P; Pinyakorn S; Rungrojrat P; Praihirunyakit P; Gerschenson M; Phanuphak P; Valcour V; Kim JH; Shikuma C;
Antivir Ther; 2012; 17(8):1521-31. PubMed ID: 23220732
[TBL] [Abstract][Full Text] [Related]
10. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection.
Shafer RW; Smeaton LM; Robbins GK; De Gruttola V; Snyder SW; D'Aquila RT; Johnson VA; Morse GD; Nokta MA; Martinez AI; Gripshover BM; Kaul P; Haubrich R; Swingle M; McCarty SD; Vella S; Hirsch MS; Merigan TC;
N Engl J Med; 2003 Dec; 349(24):2304-15. PubMed ID: 14668456
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) in Thai HIV-infected patients.
Kiertiburanakul S; Khongnorasat S; Rattanasiri S; Sungkanuparph S
J Med Assoc Thai; 2007 Feb; 90(2):237-43. PubMed ID: 17375626
[TBL] [Abstract][Full Text] [Related]
12. Reduced dose of stavudine and lipoatrophy in HIV-infected patients in Cameroon.
Cournil A; Coudray M; Kouanfack C; Essomba CN; Tonfack CA; Biwolé-Sida M; Delaporte E; Bork K; Laurent C
Antivir Ther; 2010; 15(7):1039-43. PubMed ID: 21041920
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-vir) in advanced HIV infection.
Getahun A; Tansuphasawadikul S; Desakorn V; Dhitavat J; Pitisuttithum P
J Med Assoc Thai; 2006 Sep; 89(9):1472-8. PubMed ID: 17100387
[TBL] [Abstract][Full Text] [Related]
14. Secure antiretroviral therapy delivery in a resource-limited setting: streamlined to minimize drug resistance and expense.
Kitkungvan D; Apisarnthanarak A; Laowansiri P; Mundy LM
HIV Med; 2008 Oct; 9(8):636-41. PubMed ID: 18643857
[TBL] [Abstract][Full Text] [Related]
15. Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies.
Hamers RL; Sigaloff KC; Wensing AM; Wallis CL; Kityo C; Siwale M; Mandaliya K; Ive P; Botes ME; Wellington M; Osibogun A; Stevens WS; Rinke de Wit TF; Schuurman R;
Clin Infect Dis; 2012 Jun; 54(11):1660-9. PubMed ID: 22474222
[TBL] [Abstract][Full Text] [Related]
16. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection.
Robbins GK; De Gruttola V; Shafer RW; Smeaton LM; Snyder SW; Pettinelli C; Dubé MP; Fischl MA; Pollard RB; Delapenha R; Gedeon L; van der Horst C; Murphy RL; Becker MI; D'Aquila RT; Vella S; Merigan TC; Hirsch MS;
N Engl J Med; 2003 Dec; 349(24):2293-303. PubMed ID: 14668455
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of starting first-line antiretroviral therapy in hepatitis B virus/HIV-coinfected patients in Ghana.
Chadwick D; Ankcorn M; Sarfo F; Phillips R; Fox Z; Garcia A; Appiah L; Bedu-Addo G; Geretti AM
J Antimicrob Chemother; 2012 Dec; 67(12):2939-42. PubMed ID: 22915461
[TBL] [Abstract][Full Text] [Related]
18. Haematological changes after switching from stavudine to zidovudine in HIV-infected children receiving highly active antiretroviral therapy.
Aurpibul L; Puthanakit T; Sirisanthana T; Sirisanthana V
HIV Med; 2008 May; 9(5):317-21. PubMed ID: 18331562
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis.
Bendavid E; Grant P; Talbot A; Owens DK; Zolopa A
AIDS; 2011 Jan; 25(2):211-20. PubMed ID: 21124202
[TBL] [Abstract][Full Text] [Related]
20. Motives for change of first-line antiretroviral therapy regimens in an unselected cohort of HIV/AIDS patients at a major referral centre in South-west Cameroon.
Dimala CA; Bechem NN; Aroke D; Kadia BM
BMC Res Notes; 2017 Nov; 10(1):623. PubMed ID: 29183354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
